Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness

July 31, 2013 updated by: Metabolic Technologies Inc.

Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness in Experienced Resistance Trained Individuals.

Study Objectives

  1. Compare beta-hydroxy-beta-methylbutyrate free acid (HMB-FA) to cold water immersion on performance recovery from an acute bout of high intensity resistance exercise.
  2. Compare HMB-FA + Cold water immersion to HMB-FA or cold water immersion.
  3. Examine the effect of these recovery modalities on markers of muscle damage, inflammation and immune function.

Subjects

Subjects (men and women, 18 - 35 y) with at least one year of resistance training experience will be recruited. Subjects will be randomly divided into one of four groups: a cold water immersion group (CW), HMB-FA, CW+HMB-FA and a control group (CT).

Study Protocol

Subjects will report to the Human Performance Laboratory (HPL) on four separate occasions. On the first visit (T1) subjects will be tested for maximal strength [one repetition-maximum (1-RM)] on the squat, dead lift and barbell lunge exercises.] On their second visit (T2) subjects will perform a lower body resistance exercise session consisting of four sets of the squat, dead lift and barbell lunge exercises. All subjects will then report back to the HPL at 24- (T3) and 48-hours (T4) post-exercise. During T3 and T4, subjects will perform four sets of the squat exercise only using the same loading pattern and rest interval length as T2. Following the T2 and T3 workouts subjects in CT will undergo no treatment; subjects in CW will be required to sit in a whirlpool tub for 10-min up to their umbilicus in water at 50° F - 54° F (10° C - 12° C); subjects in HMB-FA will be provided the supplement 30 min prior each workout and CW+HMB-FA will be administered together at time points describe above.

Statistical Analysis

Statistical evaluation of performance and biochemical changes will be accomplished using a repeated measures analysis of variance (ANOVA).

Study Overview

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Orlando, Florida, United States, 32816
        • University of Central Florida, Sport and Exercise Science

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • At least one-year of resistance training experience
  • Free of any physical limitations (determined by health and activity questionnaire).
  • Between the ages of 18 and 35

Exclusion Criteria:

  • Inability to perform physical exercise (determined by health and activity questionnaire)
  • Taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire).
  • Any chronic illness that causes continuous medical care
  • Taking any type of prescription or over-the-counter medication, having any chronic illness causing you to seek medical care, pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control
Placebo supplement given prior to exercise and two times per day following exercise
Experimental: cold water immersion
Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
Experimental: HMB-FA
beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
Experimental: cold water immersion group + HMB-FA
beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximal muscle strength
Time Frame: Change from baseline over 48 hours post-exercise.
The 1-RM tests will be performed to assess maximal muscle strength.
Change from baseline over 48 hours post-exercise.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle damage
Time Frame: Change from baseline over 48 hours post-exercise.
Serum creatine kinase and myoglobin concentrations will be analyzed as markers of muscle damage.
Change from baseline over 48 hours post-exercise.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle soreness
Time Frame: Change from baseline over 48-hours post-exercise.
Subjects will be asked to rate their degree of lower body muscle soreness using a 15-cm visual analog scale (VAS).
Change from baseline over 48-hours post-exercise.
Lower body power
Time Frame: Change from baseline over 48 hours post-exercise.
Lower body power during the squat exercise protocol will be measured each repetition with a Tendo™ Power Output Unit.
Change from baseline over 48 hours post-exercise.
Immune Markers
Time Frame: Change from baseline over 48 hours post-exercise.
Immune (IL-6, IL-10, Macrophage inflammatory protein-1β, tumor necrosis factor-α) markers will be analyzed.
Change from baseline over 48 hours post-exercise.
C-reactive protein
Time Frame: Change from baseline over 48 hours post-exercise.
The Inflammatory marker, C-reactive protein, will be analyzed.
Change from baseline over 48 hours post-exercise.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2012

Primary Completion (Actual)

April 1, 2013

Study Completion (Actual)

April 1, 2013

Study Registration Dates

First Submitted

February 13, 2013

First Submitted That Met QC Criteria

February 14, 2013

First Posted (Estimate)

February 18, 2013

Study Record Updates

Last Update Posted (Estimate)

August 1, 2013

Last Update Submitted That Met QC Criteria

July 31, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • MTI2013-CS01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Damage

Clinical Trials on Placebo

Subscribe